Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine Dosing and Postoperative Delirium in Anxious Elderly Gastrointestinal Cancer Patients
ChiCTR2500106981Phase 4Not yet recruiting
- Sponsor
- Wuhan Central Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in postoperative delirium (POD), post-operative cognitive decline (POCD), anxiety disorder and 1 more (4 arms), sponsored by Wuhan Central Hospital. Primary endpoints: Postoperative delirium and Postoperative cognitive function. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postoperative delirium (POD)post-operative cognitive decline (POCD)anxiety disordergastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR2500106981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106981.